Targeted gene therapy of autoimmune diseases: advances and prospects.

Abstract:

:Idealized gene therapy of autoimmune diseases would mean getting the right drug to the right place at the right time to affect the right mechanism of action. In other words, a specific gene therapy strategy needs to have functional, spatial and temporal specificity. Functional specificity implies targeting the cellular, molecular and/or genetic mechanisms relevant to the disease, without affecting nondiseased organs or tissues through mechanisms that cause adverse effects. Spatial specificity means the delivery of the therapeutic agent exclusively to sites and cells that are relevant to the disease. Temporal specificity is, in principle, synonymous with controlled on-demand expression of the therapeutic gene and thus represents a major safety feature. This article reviews recent advances in strategies to use gene therapy in the treatment of autoimmune diseases.

authors

Creusot RJ,Fathman CG,Müller-Ladner U,Tarner IH

doi

10.1586/1744666X.1.3.385

subject

Has Abstract

pub_date

2005-09-01 00:00:00

pages

385-404

issue

3

eissn

1744-666X

issn

1744-8409

journal_volume

1

pub_type

杂志文章
  • The relationship between B7 homologous 1 with interleukin-4, interleukin-17 and interferon gamma in patients with allergic rhinitis.

    abstract::Background: The etiology of allergic rhinitis includes an increase in cytokine levels, including IL- 4, IL-13, IL-17, and reduction in B7 homologous 1 (B7-H1) or programmed cell death-1 ligand-1 (PD-L1), a new member of the CD28: B7 stimulant molecule family. The aim of this study was to determine the relationship bet...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2019.1637256

    authors: Nasiri Kalmarzi R,Fakhimi R,Manouchehri F,Ataee P,Naleini N,Babaei E,Azadi N,Rabeti K,Kooti W

    更新日期:2019-08-01 00:00:00

  • Immunotherapy: a new horizon for egg allergy?

    abstract::Egg allergy is the second most frequent food allergy in children of the Western Countries, with an overall prevalence of 1-3%. Today strict avoidance diet is the only treatment, but its feasibility is difficult to obtain in childhood because of the large amount of egg proteins present in different foods. From 1998, a ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.901887

    authors: Praticò AD,Mistrello G,La Rosa M,Del Giudice MM,Marseglia G,Salpietro C,Leonardi S

    更新日期:2014-05-01 00:00:00

  • Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.

    abstract:INTRODUCTION:Common variable immunodeficiency (CVID) comprises a large heterogeneous group of patients with primary antibody deficiency. Areas covered: The affected patients are characterized by increased susceptibility to infections and low levels of serum immunoglobulin. However, enteropathy, granulomatous organ infi...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1224664

    authors: Azizi G,Abolhassani H,Asgardoon MH,Alinia T,Yazdani R,Mohammadi J,Rezaei N,Ochs HD,Aghamohammadi A

    更新日期:2017-02-01 00:00:00

  • Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.

    abstract::Inflammatory bowel diseases share common pathogenetic mechanisms that are not yet completely understood. It is clear, however, that the expression and production of cytokines in response to inflammation plays a key role in mediating the migration of activated leukocytes. The process of angiogenesis and the expression ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.10.40

    authors: Fiorino G,Correale C,Fries W,Repici A,Malesci A,Danese S

    更新日期:2010-07-01 00:00:00

  • CD4+CD25+ regulatory T-cell therapy.

    abstract::Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) expressing forkhead transcript factor box P3 have been established as a key regulator for the control of autoimmunity. A growing body of experiments in animal models has provided compelling evidence that the adoptive transfer of CD4(+)CD25(+) Tregs can cure ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.3.387

    authors: Jiang S,Lechler RI,Lombardi G

    更新日期:2006-05-01 00:00:00

  • The roles of myeloid-derived suppressor cells in transplantation.

    abstract::CD11b(+)Gr1(+) myeloid-derived suppressor cells (MDSCs) are an important regulatory innate cell population and have significant inhibitory effect on T cell-mediated responses. In addition to their negative role in cancer development, MDSCs also exert strong regulatory effects on transplantation and autoimmunity. In ma...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.948424

    authors: Wu T,Zhao Y,Zhao Y

    更新日期:2014-10-01 00:00:00

  • Occupational asthma: risk factors, diagnosis and preventive measures.

    abstract::In adulthood, new or recurrent asthma is caused by work in approximately 10% of cases. The term occupational asthma is reserved for those cases arising from respiratory hypersensitivity to a specific workplace agent; in others (work-exacerbated asthma) the mechanism is of nonspecific airway irritation on a background ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.1.1.123

    authors: Cullinan P

    更新日期:2005-05-01 00:00:00

  • Abatacept for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1579642

    authors: Pombo-Suarez M,Gomez-Reino JJ

    更新日期:2019-04-01 00:00:00

  • Pathogens and immunologic memory in asthma: what have we learned?

    abstract::Animal models and clinical studies of asthma have generated important insights into the first effector phase leading to the development of allergic airway disease and bronchial hyper-reactivity. In contrast, mechanisms related to asthma chronicity or persistence are less well understood. The CD4(+) T-helper 2 lymphocy...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.1.4.589

    authors: Aronica MA,Vogel N

    更新日期:2005-11-01 00:00:00

  • Dendritic cell-based therapy in Type 1 diabetes mellitus.

    abstract::Dendritic cell (DC) immunotherapy is a clinical reality. Despite two decades of considerable data demonstrating the feasibility of using DCs to prolong transplant allograft survival and to prevent autoimmunity, only now are these cells entering clinical trials in humans. Type 1 diabetes is the first autoimmune disorde...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.8

    authors: Phillips B,Giannoukakis N,Trucco M

    更新日期:2009-05-01 00:00:00

  • New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

    abstract:INTRODUCTION:Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1454835

    authors: Carrascosa JM,Del-Alcazar E

    更新日期:2018-04-01 00:00:00

  • Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.

    abstract::Intravenous immunoglobulin (IVIg) products are derived from pooled human plasma from thousands of donors and have been used for the treatment of primary immunodeficiency disorders for more than 30 years. IVIg products are also effective in the treatment of autoimmune and inflammatory disorders, however, the precise me...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.10

    authors: Jordan SC,Toyoda M,Vo AA

    更新日期:2011-05-01 00:00:00

  • Baricitinib for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is characterized by systemic synovitis causing joint destruction. With the development of biological disease-modifying anti-rheumatic drugs (bDMARDs) and combination of conventional DMARDs, clinical remission is perceived as an appropriate and realistic goal in many patients. Howe...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1214576

    authors: Kubo S,Nakayamada S,Tanaka Y

    更新日期:2016-09-01 00:00:00

  • Hypoallergenic molecules for subcutaneous immunotherapy.

    abstract::Although a large part of the population suffers from allergies, a cure is not yet available. Allergen-specific immunotherapy (AIT) offers promise for these patients. AIT has proven successful in insect and venom allergies; however, for food allergy this is still unclear. In this editorial we focus on the recent advanc...

    journal_title:Expert review of clinical immunology

    pub_type: 社论,评审

    doi:10.1586/1744666X.2016.1103182

    authors: Jongejan L,van Ree R,Poulsen LK

    更新日期:2016-01-01 00:00:00

  • Use of rituximab in multiple sclerosis: current progress and future perspectives.

    abstract::In recent years, new insights into the immunological pathways in multiple sclerosis (MS) have been detected. This increasing knowledge has led to more distinct treatment options in modifying the disease course of MS. In 2006, natalizumab, an alpha4-integrin monoclonal antibody, introduced a new era of MS treatment. An...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.5.573

    authors: Reske D,Haupt WF

    更新日期:2008-09-01 00:00:00

  • Targeting signaling pathways with small molecules to treat autoimmune disorders.

    abstract::Chronic activation of immune responses, mediated by inflammatory mediators and involving different effector cells of the innate and acquired immune system characterizes autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and septic shock syndrome. MAPKs are crucial intracellular m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.1.93

    authors: Kaminska B,Swiatek-Machado K

    更新日期:2008-01-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • STAT1 and STAT3 mutations: important lessons for clinical immunologists.

    abstract:INTRODUCTION:The transcription factors signal transducer and activator of transcription (STAT) 1 and STAT3 fulfill fundamental functions in nonimmune and immune cells. The description and follow-up of patients with germline mutations that result in either loss-of-function or gain-of-function have contributed to our und...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1531704

    authors: Olbrich P,Freeman AF

    更新日期:2018-12-01 00:00:00

  • The evolving concept of SLE comorbidities.

    abstract:INTRODUCTION:The survival of SLE patients has improved significantly over the past few decades placing them at increased risk of cardiovascular disease (CVD), malignancies, and osteoporosis, among other comorbidities. The aim of this review was to assess the incidence and prevalence of comorbidities in these patients a...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2017.1327353

    authors: González LA,Alarcón GS

    更新日期:2017-08-01 00:00:00

  • Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease.

    abstract::Probiotics have had many applications in the past few years, and inflammatory conditions of the GI tract--including chronic disorders such as inflammatory bowel disease (IBD)--have received the most attention by investigators. In fact, the experimental basis to expect clinical efficacy of probiotics in IBD is quite ro...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.09.70

    authors: Guandalini S

    更新日期:2010-01-01 00:00:00

  • Remestemcel-L for the treatment of graft versus host disease.

    abstract:INTRODUCTION:Remestemcel-L, a third-party, off-the-shelf preparation of bone-marrow derived mesenchymal stromal cells (MSCs), has been developed for experimental use in acute graft-versus-host disease (aGvHD) and other immune-mediated conditions. Several preclinical and clinical studies have indeed suggested the potent...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1208086

    authors: Locatelli F,Algeri M,Trevisan V,Bertaina A

    更新日期:2017-01-01 00:00:00

  • Protease inhibitors in respiratory disease: focus on asthma and chronic obstructive pulmonary disease.

    abstract::Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are a major health burden on society and current treatment modalities for these diseases have not significantly changed over the past 40 years. The only major pharmacological advancement for the treatment of these diseases has been ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.3.365

    authors: Venkatasamy R,Spina D

    更新日期:2007-05-01 00:00:00

  • Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies.

    abstract:BACKGROUND:Biological drugs, mainly interleukin (IL)-1 and IL-6 antagonists, but also tumor necrosis factor (TNF) inhibitors, have been used in the treatment of adult onset Still's disease patients (AOSD). METHODS:We summarised the available evidence for the effectiveness of biologic drugs in AOSD. A systematic review...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/1744666X.2017.1375853

    authors: Ruscitti P,Ursini F,Cipriani P,De Sarro G,Giacomelli R

    更新日期:2017-11-01 00:00:00

  • Abrocitinib for the treatment of atopic dermatitis.

    abstract:INTRODUCTION:Janus kinase (JAK) inhibitors are emerging treatments in dermatology. Also known as JAKinibs, these agents target JAK-signal transducers and activators of transcription (JAK-STAT) pathway for intracellular signaling. Among the various immune-mediated inflammatory skin diseases that the JAK-STAT pathway pla...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2021.1828068

    authors: Crowley EL,Nezamololama N,Papp K,Gooderham MJ

    更新日期:2020-10-01 00:00:00

  • Dietary therapies for eosinophilic esophagitis.

    abstract::Eosinophilic esophagitis (EoE) represents a prevalent chronic esophageal disorder. Since the condition was first described, its pathophysiology has been known to have an immune-allergic origin, but the high response rate to dietary therapies based on feeding patients exclusively with amino acid-based elemental formula...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.856263

    authors: Arias A,Lucendo AJ

    更新日期:2014-01-01 00:00:00

  • Brodalumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monocl...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1246957

    authors: Galluzzo M,D'adamio S,Bianchi L,Talamonti M

    更新日期:2016-12-01 00:00:00

  • Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.

    abstract::The past years have seen the publication of several studies on seronegative spondylarthritides (SpA) and cardiovascular risk as a result of new insights into the connection between inflammation and atherogenesis. Although the overall cardiovascular disease is a complex entity, chronic inflammation of SpA is known to c...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.875468

    authors: Ingegnoli F,Gualtierotti R,Artusi C,Lubrano E

    更新日期:2014-02-01 00:00:00

  • Treatment and monitoring of hypersensitivity pneumonitis.

    abstract:INTRODUCTION:Hypersensitivity pneumonitis (HP) is an immunologically induced lung disease that develops after inhalation of certain environmental antigens only in subjects with susceptibility to antigens. Therefore, both environmental and host immunological factors play important roles in the aetiology and pathogenesis...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1182426

    authors: Miyazaki Y,Tsutsui T,Inase N

    更新日期:2016-09-01 00:00:00

  • Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.

    abstract:INTRODUCTION:Secondary immunodeficiency is becoming a greater medical concern as the usage of immunosuppressive and biological treatments has increased. Individuals with certain medical conditions, such as hematological malignancies, can also have secondary immunodeficiency. Immunoglobulin replacement therapy (IGRT), w...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1788939

    authors: Patel V,Cowan J

    更新日期:2020-07-01 00:00:00

  • Cardiovascular comorbidities in antiphospholipid syndrome.

    abstract::Antiphospholipid syndrome is an autoimmune disease characterized by venous and/or arterial thrombosis and/or recurrent fetal loss and the presence of antiphospholid antibodies. Among the causes of death of antiphospholipid syndrome there are the myocardial infarction and stroke. Comorbidities could worsen the evolutio...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.837261

    authors: Muniz Caldas CA,Freire de Carvalho J

    更新日期:2013-10-01 00:00:00